Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug ...

Stroke is the fourth leading cause of death among Hispanic men and the third leading cause for Hispanic women in the United States. Yet, according to CDC reports, only 58% of Hispanic adults can ...

A phase 1/2 trial (NCT06065462) is currently underway to evaluate the safety and efficacy of PP2A inhibition with LB-100 plus dostarlimab-gxly (Jemperli) in recurrent ovarian clear cell carcinoma. 3 ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...

Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study A nationwide ...

PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new ...